Home > Boards > US OTC > Biotechs > Sangamo Biosciences Inc. (SGMO)

$SGMO hitting the investor circuits hard, first Cantor

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Triple9 Member Profile
 
Followed By 55
Posts 1,194
Boards Moderated 1
Alias Born 01/13/17
160x600 placeholder
Sangamo Therapeutics Appoints Bettina M. Cockroft, MD, MBA, as Senior Vice President and Chief Medical Officer Business Wire - 9/30/2019 4:15:00 PM
Sangamo Therapeutics Announces Participation at Upcoming Investor Conferences Business Wire - 9/30/2019 8:30:00 AM
Initial Statement of Beneficial Ownership (3) Edgar (US Regulatory) - 9/26/2019 6:16:05 PM
Sangamo Therapeutics Announces Participation at Upcoming Investor Conferences Business Wire - 8/30/2019 8:30:00 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 8/14/2019 5:11:36 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 8/14/2019 5:05:41 PM
Quarterly Report (10-q) Edgar (US Regulatory) - 8/7/2019 4:45:52 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 8/7/2019 4:38:07 PM
Sangamo Therapeutics Reports Second Quarter 2019 Financial Results Business Wire - 8/7/2019 4:01:00 PM
Sangamo Therapeutics Announces Participation at Upcoming Investor Conferences Business Wire - 8/6/2019 4:05:00 PM
Initial Statement of Beneficial Ownership (3) Edgar (US Regulatory) - 8/6/2019 4:03:48 PM
Sangamo Therapeutics Appoints Gary H. Loeb as Executive Vice President and General Counsel Business Wire - 7/31/2019 4:15:00 PM
Sangamo Therapeutics Announces Second Quarter 2019 Conference Call and Webcast Business Wire - 7/31/2019 4:05:00 PM
Sangamo Announces Nature Biotechnology Publication of New Strategies for Optimizing the Specificity of Gene Editing Nucleases Business Wire - 7/29/2019 11:00:00 AM
Sangamo et Pfizer annoncent des résultats de phase 1/2 mis à jour pour la thérapie génique expérimentale de l’hémoph... Business Wire - 7/8/2019 10:05:00 AM
Sangamo Therapeutics Up 17%; Unveiled Updated Study Data Dow Jones News - 7/8/2019 8:43:00 AM
Sangamo & Pfizer Announce Updated Phase 1/2 Results for SB-525 Investigational Hemophilia A Gene Therapy Showing Sustained In... Business Wire - 7/5/2019 11:15:00 PM
 Sangamo Therapeutics Announces Nature Medicine Publication Detailing the Activity of Disease Allele-Selective Zinc Finger P... Business Wire - 7/1/2019 11:00:00 AM
Sangamo Announces Upcoming Presentation Of Investigational SB-525 Hemophilia A Gene Therapy Data At ISTH 2019 PR Newswire (US) - 6/21/2019 9:16:00 AM
Initial Statement of Beneficial Ownership (3) Edgar (US Regulatory) - 6/18/2019 5:03:05 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 6/14/2019 4:03:08 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/12/2019 5:14:04 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/12/2019 5:10:50 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/12/2019 5:09:29 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/12/2019 5:08:23 PM
Triple9   Friday, 09/29/17 09:19:33 AM
Re: None
Post # of 340 
$SGMO hitting the investor circuits hard, first Cantor Fitzgerald and now

"RICHMOND, Calif., Sept. 28, 2017 /PRNewswire/ -- Sangamo Therapeutics, Inc. (Nasdaq: SGMO) announced today that Sandy Macrae, M.B., Ch.B., Ph.D., Sangamo's chief executive officer, will participate in the following conferences in October.

2017 Cell & Gene Meeting on the Mesa, La Jolla, CA, October 4-6, 2017

Dr. Macrae will participate in a panel discussion on gene editing at 9:15 a.m. PT on Thursday, October 5th, and is scheduled to present a company overview later that afternoon during the annual Partnering Forum at 2:15 p.m. PT.

Jefferies Gene Technology Investor Summit, New York, NY, October 12, 2017

Dr. Macrae is scheduled to present a company overview at 2:50 p.m. ET on Tuesday, October 12th.

The presentations will be webcast live and may be accessed via a link on the Sangamo Therapeutics website in the Investors and Media section under Events and Presentations. A replay of the presentations will be archived on the Sangamo website for two weeks after the event."



Know What You Own. My posts should not be construed as investment advice.
Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist